AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2979681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg
Number of subjects: 8
Study 2979681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2979681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1300 mg, 36 mmol)
Number of subjects: 8
Study 2979681 — intervention group
Group type: COMPARATOR
Intervention: Control for aspirin (36 mmol HCl)
Number of subjects: 8
Study 30348098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling (measured by FES-I)
Number of subjects: 155
Study 30348098 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 155
Study 30348098 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 155
Study 27437883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 27437883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 24925464 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with S-1 (GS)
Number of subjects: 193
Study 24925464 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (Gem)
Number of subjects: 193
Study 22639135 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine labor epidural (bolus concentration 0.25 % or less; infusion concentration 0.125 % or less)
Number of subjects: 144
Study 22639135 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal‐epidural procedure (morphine 0.20 mg, fentanyl 25 µg and hyperbaric bupivacaine 2.5 mg)
Number of subjects: 144
Study 22639135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-augmented labor
Number of subjects: 144
Study 22639135 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced partum
Number of subjects: 144
Study 20201992 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 417
Study 17707079 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention for PA and FI
Number of subjects: 567
Study 17707079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention (PA at baseline and FI at 3 months)
Number of subjects: 567
Study 17707079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention (FI at baseline and PA at 3 months)
Number of subjects: 567
Study 17707079 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 567
Study 16883901 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 294
Study 16883901 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Western group)
Number of subjects: 294
Study 16883901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of TCM and chemotherapy (Integrative group)
Number of subjects: 294
Study 12823702 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTAC solution
Number of subjects: 60
Study 12823702 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser application (11 mm focal distance, 4 Hz frequency, 200 mJ energy, 2.25 W potency, 62 J total energy, 1 min application time)
Number of subjects: 60
Study 12823702 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 60
Study 10608756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal zidovudine treatment for 2 weeks
Number of subjects: 310
Study 10608756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 10608756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal zidovudine treatment
Number of subjects: 310
Study 8857501 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-segment model of LV segmentation
Number of subjects: 105
Study 8857501 — intervention group
Group type: COMPARATOR
Intervention: 11-segment model of LV segmentation
Number of subjects: 105
Study 1514169 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (500 U heparin/h for 30 h)
Number of subjects: 6
Study 1514169 — intervention group
Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 6
Study 6370007 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (R)‐15‐methyl prostaglandin E2
Number of subjects: 46
Study 6370007 — intervention group
Group type: COMPARATOR
Intervention: Antacid (usually Mylanta II)
Number of subjects: 46
Study 31246661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy
Number of subjects: 72
Study 31246661 — intervention group
Group type: EXPERIMENTAL
Intervention: Promestriene (10 mg intravaginal cream 3 times a week)
Number of subjects: 72
Study 31246661 — intervention group
Group type: COMPARATOR
Intervention: Vaginal lubricant application
Number of subjects: 72
Study 29467849 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT combined with chemotherapy
Number of subjects: 150
Study 29467849 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy and chemotherapy
Number of subjects: 150
Study 26760605 — intervention group
Group type: COMPARATOR
Intervention: 4L PEG
Number of subjects: 2802
Study 26760605 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L PEG plus ascorbate (PEG-A)
Number of subjects: 2802
Study 26760605 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L PEG with citrate and simethicone plus bisacodyl (PEG-CS)
Number of subjects: 2802
Study 24571824 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy rehabilitation program (Takla‐O'Donnell Protocol) including seven individual 30‐minute sessions
Number of subjects: 100
Study 24571824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional physiotherapy management)
Number of subjects: 100
Study 22954027 — intervention group
Group type: EXPERIMENTAL
Intervention: Early admission (within two months)
Number of subjects: 0
Study 22954027 — intervention group
Group type: COMPARATOR
Intervention: Usual admission (after an average waiting time of eight months)
Number of subjects: 0
Study 20051942 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE)
Number of subjects: 100
Study 20051942 — intervention group
Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 100
Study 17481836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweat patches worn for 7 days after cessation of cannabis use
Number of subjects: 11
Study 17481836 — intervention group
Group type: COMPARATOR
Intervention: Oral doses of up to 14.8 mg THC/day for five consecutive days
Number of subjects: 11
Study 15830180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF)
Number of subjects: 41
Study 15830180 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 41
Study 15830180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF) for non-painful neuropathy
Number of subjects: 41
Study 15830180 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for non-painful neuropathy
Number of subjects: 41
Study 15830180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF) for painful neuropathy
Number of subjects: 41
Study 15830180 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for painful neuropathy
Number of subjects: 41
Study 11938417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin 200 U/kg/day and iron 1mg/kg/day
Number of subjects: 20
Study 11938417 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study 10484096 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (trained twice)
Number of subjects: 9
Study 10484096 — intervention group
Group type: COMPARATOR
Intervention: Group I (trained once)
Number of subjects: 9
Study 10484096 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound technician (Group III)
Number of subjects: 9
Study 10484096 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall residents
Number of subjects: 9
Study 8567443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairs of clicks with interstimulus intervals under 8-9 ms
Number of subjects: 0
Study 8567443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairs of clicks with interstimulus intervals from 12 to 1 ms
Number of subjects: 0
Study 8567443 — intervention group
Group type: COMPARATOR
Intervention: Stimulus alone
Number of subjects: 0
Study 2198378 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg xipamide/day
Number of subjects: 22
Study 2198378 — intervention group
Group type: COMPARATOR
Intervention: 200 mg spironolactone/day combined with 40 mg of furosemide every other day
Number of subjects: 22
Study 602716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Decadron, 2 mg 3 times a day for 4 days)
Number of subjects: 56
Study 602716 — intervention group
Group type: COMPARATOR
Intervention: Control (64 patients, no treatment mentioned)
Number of subjects: 56
Study 30884705 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded sorghum
Number of subjects: 24
Study 30884705 — intervention group
Group type: COMPARATOR
Intervention: Extruded wheat
Number of subjects: 24
Study 28693983 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 44
Study 28693983 — intervention group
Group type: COMPARATOR
Intervention: Sedimentation
Number of subjects: 44
Study 26044872 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (2 mg/day)
Number of subjects: 100
Study 26044872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24379010 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (LE)
Number of subjects: 94
Study 24379010 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT emulsion-based PN
Number of subjects: 94
Study 21564156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivatives and synthetic bone graft (EMD/SBG)
Number of subjects: 73
Study 21564156 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivatives (EMD)
Number of subjects: 73
Study 18765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 0.05% (tCsA) eye drops
Number of subjects: 31
Study 18765950 — intervention group
Group type: COMPARATOR
Intervention: Control group (left eyes)
Number of subjects: 31
Study 18765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (tCsA) and Control group
Number of subjects: 31
Study 18765950 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and tCsA
Number of subjects: 31
Study 16846555 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (90 microg, QID)
Number of subjects: 173
Study 16846555 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (180 microg)
Number of subjects: 173
Study 16846555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 16846555 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 173
Study 16846555 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol
Number of subjects: 173
Study 16846555 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol and racemic albuterol
Number of subjects: 173
Study 14984495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection (UKALL X protocol, n = 40)
Number of subjects: 111
Study 14984495 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion (UKALL XI protocol, n = 71)
Number of subjects: 111
Study 11242268 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion using autografts or allografts and anterior plating
Number of subjects: 106
Study 11242268 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion using anterior plating
Number of subjects: 106
Study 11242268 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion
Number of subjects: 106
Study 9645886 — intervention group
Group type: COMPARATOR
Intervention: Initial medical therapy
Number of subjects: 686
Study 9645886 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical revascularization
Number of subjects: 686
Study 7832572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic tests of muscle function and muscle histology
Number of subjects: 20
Study 7832572 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle histomorphometry
Number of subjects: 20
Study 7832572 — intervention group
Group type: COMPARATOR
Intervention: Histomorphometric examination of muscle needle biopsy
Number of subjects: 20
Study 7832572 — intervention group
Group type: COMPARATOR
Intervention: Lactate profiles after ischaemic forearm exercise
Number of subjects: 20
Study 7832572 — intervention group
Group type: COMPARATOR
Intervention: Basal serum lactate levels
Number of subjects: 20
Study 7832572 — intervention group
Group type: COMPARATOR
Intervention: Type II fibre atrophy factors
Number of subjects: 20
Study 2851762 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin + etoposide (DDP/VP)
Number of subjects: 150
Study 2851762 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide + etoposide (cyclo/VP)
Number of subjects: 150
Study 2851762 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP/VP
Number of subjects: 150
Study 2851762 — intervention group
Group type: COMPARATOR
Intervention: cyclo/VP
Number of subjects: 150
Study 2851762 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage regimen with adriamycin + vindesine (ADM/VDS)
Number of subjects: 150
Study 30428290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg per day for 14 days, then 20 mg per day for 14 days)
Number of subjects: 240
Study 30428290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 30428290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 240
Study 28324886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (USS)
Number of subjects: 22966
Study 28324886 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 22966
Study 28324886 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat screening (USS and MMS)
Number of subjects: 22966
Study 28324886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening (USS and MMS)
Number of subjects: 22966
Study 28324886 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22966
Study 25760973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to chemotherapy (cisplatin and paclitaxel)
Number of subjects: 0
Study 25760973 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and paclitaxel (control)
Number of subjects: 0
Study 22153054 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulation
Number of subjects: 38
Study 22153054 — intervention group
Group type: COMPARATOR
Intervention: Mannequin-based simulation
Number of subjects: 38
Study 21320368 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-S meal (solid breakfast)
Number of subjects: 15
Study 21320368 — intervention group
Group type: COMPARATOR
Intervention: PR-B meal (beverage breakfast)
Number of subjects: 15
Study 18463479 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.3 base curve
Number of subjects: 0
Study 18463479 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.6 base curve
Number of subjects: 0
Study 18463479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype lens
Number of subjects: 0
Study 18463479 — intervention group
Group type: COMPARATOR
Intervention: Senofilcon A lens
Number of subjects: 0
Study 16524859 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg orally 3 times a day)
Number of subjects: 40
Study 16524859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12930186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic training (EXP)
Number of subjects: 38
Study 12930186 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 38
Study 10606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg twice daily
Number of subjects: 20
Study 10606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 20
Study 10606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 20
Study 10606839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9105568 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (continuous oral 17 beta‐estradiol 2 mg/day combined with norethisterone acetate 1 mg/day)
Number of subjects: 70
Study 9105568 — intervention group
Group type: COMPARATOR
Intervention: E2/MPA (transdermal 17 beta‐estradiol 50 micrograms/day combined with cyclic medroxyprogesterone acetate 10 mg/day)
Number of subjects: 70
Study 8407399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant brachytherapy (BRT)
Number of subjects: 126
Study 8407399 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (no BRT)
Number of subjects: 126
Study 3084269 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose infusion for 2 hours
Number of subjects: 0
Study 3084269 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% amino acid infusion for 2 hours
Number of subjects: 0
Study 3084269 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 0
Study 31977921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fireground interventions (self‐contained breathing apparatus, entry team wash down, contaminated equipment isolation, personnel showering and washing of gear)
Number of subjects: 0
Study 31977921 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared sauna treatment
Number of subjects: 0
Study 31977921 — intervention group
Group type: COMPARATOR
Intervention: Standard postfire care
Number of subjects: 0
Study 28846163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg
Number of subjects: 240
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg IV‐TXA before skin incision (group A)
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg IV‐TXA 3 hours later (group B)
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Two boluses of 10 mg/kg IV‐TXA at 3 and 6 hours later (group C)
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Total blood loss
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein and interleukin 6 levels
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale pain score
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb swelling ratio
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital for Surgery Score
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay (LOH)
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion rate
Number of subjects: 151
Study 27262419 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis
Number of subjects: 151
Study 25722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg q24h for 9 months)
Number of subjects: 64
Study 25722196 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (300 mg q24h for 9 months)
Number of subjects: 64
Study 23052809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin 1 g
Number of subjects: 254
Study 23052809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 20642418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 3-monthly spirometry with regular medical review
Number of subjects: 305
Study 20642418 — intervention group
Group type: COMPARATOR
Intervention: Group B: Spirometry only before and after the trial
Number of subjects: 305
Study 20642418 — intervention group
Group type: COMPARATOR
Intervention: Group C: Usual care
Number of subjects: 305
Study 18821166 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting unrelated semantic information during the fragment completion test
Number of subjects: 0
Study 18821166 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating both the solutions and blocking words for a particular fragment at study
Number of subjects: 0
Study 18821166 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed-forgetting instructions
Number of subjects: 0
Study 18821166 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour delay
Number of subjects: 0
Study 15722804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 95
Study 12061361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of indomethacin (n = 14)
Number of subjects: 32
Study 12061361 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of indomethacin (n = 18)
Number of subjects: 32
Study 10512905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined echoplanar MRI diffusion‐weighted imaging (DWI), perfusion imaging (PI), and magnetic resonance angiography (MRA)
Number of subjects: 34
Study 7560032 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured elbow (IE) radiographs
Number of subjects: 25
Study 7560032 — intervention group
Group type: COMPARATOR
Intervention: Both injured and uninjured elbow (UE) radiographs
Number of subjects: 25
Study 2110199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg per injection of IFN, subcutaneous injections three times weekly
Number of subjects: 45
Study 2110199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg of IFN, subcutaneous injections three times weekly
Number of subjects: 45
Study 2110199 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneous injections three times weekly
Number of subjects: 45
Study 6110582 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose oral contraceptives (50 microgram of estrogen)
Number of subjects: 500
Study 6110582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives (30 microgram of estrogen)
Number of subjects: 500
Study 6110582 — intervention group
Group type: COMPARATOR
Intervention: Both standard-dose and low-dose oral contraceptives
Number of subjects: 500